BioCentury | Feb 11, 2020
Product Development

Feb. 10 Product Development Quick Takes: Priority Review for Gilead CAR T cell therapy; plus Zai, Aquestive, Biohaven, Oculis, Blue Water, GlycoMimetics, Fluidi

Gilead’s second CAR T under Priority Review  Gilead Sciences Inc. (NASDAQ:GILD) said FDA accepted and granted Priority Review to a BLA for KTE-X19 to treat adults with relapse or refractory mantle cell lymphoma. The anti-CD19...
BioCentury | Nov 9, 2019
Product Development

Sickle cell disease poised for fresh infusion of hemoglobin-based endpoints

As new therapies designed to cut off sickle cell disease pathology at the root advance through the clinic, the field is moving beyond endpoints centered on pain crises to readouts based on hemoglobin. A single,...
BC Extra | Aug 6, 2019
Clinical News

Next up for GlycoMimetics after tanking in sickle cell disease

Despite plunging 69% to $2.80 on Monday after the Phase III miss of sickle cell disease candidate rivipansel, GlycoMimetics could still turn things around. The small cap has another shot on goal with Phase III...
BioCentury | Jul 6, 2018
Emerging Company Profile

Tethering bleeding risk

With a mechanism that blocks thrombosis-contributing cells but not coagulation, Tetherex Pharmaceuticals Inc.’s pan-selectin inhibitor SelK2 could treat venous thromboembolism with little to no risk of bleeding. Chairman and CEO Scott Rollins said while antithrombotic...
Completed Offerings | Apr 20, 2018
Completed Offerings

Tetherex raises $50M series B, plans Phase II for pan-selectin inhibitor

Tetherex Pharmaceuticals Inc. (Oklahoma City, Okla.) said it closed a $50 million series B round on April 18 led by existing investor MPM Capital. I2E, Tetherex board member Philip Jones and other undisclosed Oklahoma-based investors...
BC Extra | Apr 18, 2018
Financial News

Tetherex raises $50M series B, plans Phase II for pan-selectin inhibitor

Tetherex Pharmaceuticals Inc. (Oklahoma City, Okla.) said it closed a $50 million series B round Wednesday led by existing investor MPM Capital. I2E, Tetherex board member Philip Jones and other undisclosed Oklahoma-based investors also participated....
BC Innovations | Nov 29, 2012
Cover Story

Multitasking E selectin

In patients with cancer, repeated rounds of chemotherapy exhaust the self-renewal capacity of hematopoietic stem cells, leading to prolonged bone marrow suppression, cytopenia and neutropenia. Now, researchers at the Mater Medical Research Institute, The University...
BC Innovations | Nov 8, 2012
Distillery Therapeutics

Indication: Hematology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hematology Neutropenia E selectin (SELE; CD62E) Mouse studies suggest blocking SELE could help prevent neutropenia during chemotherapy or radiation therapy. In mice receiving chemotherapy or radiotherapy,...
BioCentury | May 14, 2012
Emerging Company Profile

Visionary: Sights on drug design

Visionary Pharmaceuticals Inc. believes a large library and computational technology that accounts for conformational changes will allow it to design small molecules that have more drug-like properties than those discovered by conventional high throughput screening....
BC Week In Review | Mar 14, 2011
Clinical News

Inhaled Bimosiamose: Phase II data

Top-line data from a double-blind, crossover, German Phase II trial in 77 patients with moderate to severe COPD showed that twice-daily inhaled Bimosiamose met the primary endpoint of significantly reducing IL-8 levels in induced sputum...
Items per page:
1 - 10 of 22